Catalog No.
DHK07701
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
Ig(G4-kappa_G4-lambda)
Clonality
Monoclonal
Target
GPRC5D, G-protein coupled receptor family C group 5 member D, T3E, T-cell surface antigen T3/Leu-4 epsilon chain, CD3e, CD3E, T-cell surface glycoprotein CD3 epsilon chain
Concentration
1.75 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q9NZD1 & P07766
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
Bispecific, JNJ-64407564, CAS: 2226212-40-2
Clone ID
Talquetamab
Emerging GPRC5D-Targeted therapies for multiple myeloma: a comprehensive review., PMID:40425184
Correction to "Weight Loss and Dysgeusia in Relapsed/Refractory Multiple Myeloma Patients Treated With Talquetamab"., PMID:40391330
Correction to "B-cell Maturation Antigen-Based Therapies Post-Talquetamab in Relapsed or Refractory Multiple Myeloma"., PMID:40391329
Practice-changing updates on multiple myeloma: highlights from the 2024 ASH annual meeting., PMID:40361170
Using bispecific antibodies in a patient with peritoneal dialysis for relapsed multiple myeloma., PMID:40356496
Phase 1 study of talquetamab, a humanized GPRC5D x CD3 bispecific antibody, in Japanese patients with relapsed/refractory MM., PMID:40343678
A German multicenter real-world analysis of talquetamab in 138 patients with relapsed/refractory multiple myeloma., PMID:40248128
Economic Impact of Elranatamab for Treatment of Patients with Relapsed or Refractory Multiple Myeloma., PMID:40225701
Real-world treatment patterns for teclistamab and talquetamab in multiple myeloma (MM): experience from 609 patients., PMID:40199861
Perspectives on Talquetamab and its Utility in the Treatment of Multiple Myeloma: Safety, Efficacy and Place in Therapy., PMID:40196851
Unveiling cardiovascular and respiratory toxicities with monoclonal antibodies in multiple myeloma: disproportionality analysis from the FDA Adverse Event Reporting System., PMID:40095047
Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1-2 study., PMID:40090350
Restarting Teclistamab and Talquetamab after Prolonged Dose Delay May Not Require Re-Step-up Dosing., PMID:40048741
Multiomic profiling of T cell lymphoma after therapy with anti-BCMA CAR T cells and GPRC5D-directed bispecific antibody., PMID:39984633
Advancements in bispecific antibodies for multiple myeloma: What's new and what lies ahead., PMID:39880754
Expert Opinion on Multiple Myeloma Treatment in Brazil in the Bispecific Antibody Era., PMID:39809660
Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma., PMID:39778168
Practical insights into bispecific antibody therapy in multiple myeloma., PMID:39729045
Anti-BCMA and GPRC5D bispecific antibodies in relapsed/refractory primary plasma cell leukemia: a case report., PMID:39676854
Comprehensive Review of Bispecific Antibody Constructs In Multiple Myeloma: Affinities, Dosing Strategies and Future Perspectives., PMID:39676006
Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy., PMID:39632797
Bispecific antibodies for the treatment of hematologic malignancies: The magic is T-cell redirection., PMID:39617677
Talquetamab in Multiple Myeloma: Efficacy, Safety, and Future Directions., PMID:39604778
Dermatological adverse events linked to talquetamab immunotherapy in multiple myeloma., PMID:39603681
Evaluation of Drug-Drug Interaction Potential of Talquetamab, a T-Cell-Redirecting GPRC5D × CD3 Bispecific Antibody, as a Result of Cytokine Release Syndrome in Patients with Relapsed/Refractory Multiple Myeloma in MonumenTAL-1, Using a Physiologically Based Pharmacokinetic Model., PMID:39285155
Talquetamab Versus Real-World Physician's Choice Treatment: Comparative Effectiveness in Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma., PMID:39271448
Matching-adjusted indirect comparison of talquetamab vs selinexor-dexamethasone and vs belantamab mafodotin in patients with relapsed/refractory multiple myeloma., PMID:39226081
Targeting GPRC5D With Talquetamab: A New Frontier in Bispecific Antibody Therapy for Relapsed/Refractory Multiple Myeloma., PMID:39192558
Structural Basis for the Recognition of GPRC5D by Talquetamab, a Bispecific Antibody for Multiple Myeloma., PMID:39181182
Real-world experience with clinical management of talquetamab in relapsed/refractory multiple myeloma: a qualitative study of US healthcare providers., PMID:39177290
Weight loss and dysgeusia in relapsed/refractory multiple myeloma patients treated with talquetamab., PMID:39157593
Nursing Considerations for the Clinical Management of Adverse Events Associated with Talquetamab in Patients with Relapsed or Refractory Multiple Myeloma., PMID:39155155
Management of Toxicities Associated with BCMA, GPRC5D, and FcRH5-Targeting Bispecific Antibodies in Multiple Myeloma., PMID:39145912
Dermatological toxicities of talquetamab, a new bispecific antibody: case series and literature review., PMID:39094121
Mass Spectrometry as Alternative Method to Identify and Monitor Non-Secretory Progressive Disease in Patients with Multiple Myeloma., PMID:38927360
B-cell maturation antigen-based therapies post-talquetamab in relapsed or refractory multiple myeloma., PMID:38895072
Clinical Management of Patients With Relapsed/Refractory Multiple Myeloma Treated With Talquetamab., PMID:38871558
T-Cell Characteristics Impact Response and Resistance to T-Cell-Redirecting Bispecific Antibodies in Multiple Myeloma., PMID:38687588
Therapeutic progress in relapsed/refractory multiple myeloma., PMID:38609727
Targeting GPRC5D in multiple myeloma., PMID:38607646
A pivotal decade for bispecific antibodies?, PMID:38465614
[Talquetamab - multiple myeloma after at least three prior lines of therapy]., PMID:38458925
Peeling Back the Layers: Recurrent Talquetamab Skin Toxicity after Supportive Stem Cell Boost in Multiple Myeloma., PMID:38447541
Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies: a national retrospective study., PMID:38432433
Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma., PMID:38402374
Phenomenon of tumor flare with talquetamab in a patient with extramedullary myeloma., PMID:38385275
GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review., PMID:38307865
For research use only. Not for human or drug use.
